Enhanced Photoaging Reversal Efficacy and Safety of 755nm Alexandrite Picosecond Laser with Diffractive Lens Array (DLA) in Conjunction with Integrated Skin Care for Skin Quality Improvement

Patients undergoing picosecond laser treatment experience skin sensitivity, compromised barrier function, increased water loss, and oxidative stress post-treatment. Inadequate postoperative care prolongs recovery and raises the risk of pigmentation issues or recurrence. Common postoperative care includes antioxidants, moisturizing sunscreen, skin whitening, spot lightening, and barrier repair treatments. Common post-procedure skincare products include (1) CE Serum (an antioxidant serum containing vitamin C, vitamin E, and ferulic acid), (2) DD Serum (a serum containing tranexamic acid, kojic acid, and niacinamide [vitamin B3], which helps reduce pigmentation), and (3) Sebum membrane repair cream [242 cream] (a newly formulated cream designed to restore the skin barrier function caused by aging). However, standardized post-picosecond laser care protocols are lacking, necessitating more clinical data and experience summaries.

This study seeks to assess the effectiveness and satisfaction of combining SkinCeuticals skin-care products (CE/DD/242) with 755nm alexandrite picosecond laser with diffractive lens array (DLA) for facial pigmentation and photoaging. It will be a prospective, single-center, evaluator-blinded, randomized spilt-face design trial. Thirty-five subjects will be recruited and randomly assigned to receive either the combined skincare products (CE/DD/242), and regular moisturizing product and sunscreen (Phyto Corrective Gel and Advanced Brightening UV Defense SPF50 PA++++) (treatment group) or regular moisturizing product and sunscreen alone (control group) following 755nm alexandrite picosecond laser with DLA. The study consists of three treatment cycles over 12 weeks, with assessments conducted at the end of each cycle. Evaluation indicators will be compared at 4, 8, and 12 weeks post-treatment to determine efficacy and satisfaction. Additionally, the redness within 3 day will be collected through phone call or visit at trial site. The study aims to explore the maintenance medical benefits of combining 755nm alexandrite picosecond laser with DLA in conjugated with SkinCeuticals skincare products for facial pigmentation and photoaging.

Inclusion criteria

• Subjects 25-65 years of age on the date of informed consent
• Fitzpatrick skin type II-V with pigmentation and photoaging on both sides of the face
• The severity of pigmentation and photoaging on both sides of the face is the same.
• Willing to receive picosecond laser treatment.
• Willing to follow the research requirements and cooperate with the process for follow-up visits.
• Subjects able to understand the written informed consent and willing to subject as evidenced by signing the informed consent

Exclusion criteria

• Women who are pregnant, breastfeeding, or planning to conceive within one year.
• Subjects with active facial melasma.
• Those with a history of skin pigmentation disorders, such as pigmentation induced by hormonal factors (pregnancy, oral contraceptives).
• Subjects with autoimmune diseases, endocrine disorders, or liver diseases that lead to changes in skin color.
• Subjects who have used skin whitening agents, steroids, or photosensitive drugs within the past three months.
• Subjects who have undergone laser treatment within the past three months.
• Those who have contraindications to picosecond laser or the CE/DD/242 products, or are allergic to the ingredients in the skincare combination products.
• Subjects with facial infections or inflammation.
• Those planning to use other medications affecting skin color during the study or in-tending to undergo other laser treatments or sunbathing.
• Subjects currently participating in other clinical trials.
• Subjects deemed unsuitable for participation in this study after evaluation by the researchers.